Nutriband Inc. (NASDAQ:NTRB) shares moved forward Monday. The Orlando, Fla.-based company, a developer of transdermal pharmaceutical products, today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on July 9, for trademark application Serial Number 98117984, covering the mark "AVERSA™." The Notice of Allowance signifies that the USPTO is expected to grant a trademark registration for this application following the completion of administrative processes.
The AVERSA™ trademark is integral to Nutriband's platform technology which can be incorporated into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. Nutriband's lead product under development is AVERSA™ Fentanyl, an abuse deterrent fentanyl transdermal system.
Nutriband, in partnership with Kindeva Drug Delivery, is progressing towards completing the scale-up of the commercial manufacturing process for AVERSA™ Fentanyl. This partnership has successfully moved from a feasibility agreement to a commercial development and clinical supply agreement aimed at manufacturing product for the upcoming human abuse potential clinical study. This study is crucial for the New Drug Application (NDA) that Nutriband plans to submit to the FDA.
This morning’s news release goes on to say that, upon completion of the commercial manufacturing process, Nutriband will file an Investigational New Drug (IND) application with the FDA. This filing will precede the pivotal laboratory and clinical evaluations needed to demonstrate the abuse-deterrent properties of AVERSA™ Fentanyl, in line with FDA Guidance.
NTRB shares took on 20 cents to $49.88.
